BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...at TCR2 Therapeutics Inc. (NASDAQ:TCRR) in 2017-19 and before that co-founded and served as CSO at Cour Pharmaceutical...
BioCentury | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

...therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in Barcelona, Cour Pharmaceutical Development Co. Inc....
BioCentury | Sep 19, 2019
Product Development

Anokion’s autoimmunity platform evolution

...two other companies have platforms to deliver autoantigens to the liver: Topas Therapeutics GmbH and Cour Pharmaceutical Development Co. Inc....
BioCentury | Aug 11, 2016
Product R&D

Selecta spreads tolerance

...cells, the engineered protein antigens will be recognized as self along with the erythrocyte components. Cour Pharmaceutical Development Co. Inc....
...AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Anokion S.A., Ecublens, Switzerland Brigham and Women's Hospital, Boston, Mass. Cour Pharmaceutical Development Co. Inc....
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...discovery or preclinical deals for GI diseases since, including deals in December and January with Cour Pharmaceutical Development Co. Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Cour Pharmaceutical Development Co. Inc....
BioCentury | Feb 4, 2016
Translation in Brief

Peanut butter fingerprints

...multiple allergens. The partners also market the mAb for urticaria. Nadeau is also working with Cour Pharmaceutical Development Co. Inc....
BioCentury | Jan 28, 2016
Translation in Brief

Enterome's Entrée

...the space of a month. Takeda's GI Drug Discovery Unit (DDU) announced a deal with Cour Pharmaceutical Development Co. Inc....
BioCentury | Jan 18, 2016
Company News

Cour Pharmaceutical, Takeda deal

...which Takeda exercises its option. The companies declined to provide further financial terms or details. Cour Pharmaceutical Development Co. Inc....
BioCentury | May 26, 2014
Company News

Cour Pharmaceutical board of directors update

Cour Pharmaceutical Development Co. Inc. , Elmhurst, Ill. Business: Inflammation, Autoimmune, Endocrine/Metabolic Appointed: Catherine Mackey as chairman, formerly SVP of worldwide R&D at Pfizer Inc. WIR Staff autoimmune Inflammation...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Inflammation

...sites of inflammation and disease symptoms compared with neutral nanoparticles or vehicle. Ongoing studies at Cour Pharmaceutical Development Co. Inc....
...doi:10.1038/scibx.2014.148 Published online Feb. 6, 2014 Patented by Getts Consulting and Project Management; licensed to Cour Pharmaceutical...
Items per page:
1 - 10 of 11
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...at TCR2 Therapeutics Inc. (NASDAQ:TCRR) in 2017-19 and before that co-founded and served as CSO at Cour Pharmaceutical...
BioCentury | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

...therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in Barcelona, Cour Pharmaceutical Development Co. Inc....
BioCentury | Sep 19, 2019
Product Development

Anokion’s autoimmunity platform evolution

...two other companies have platforms to deliver autoantigens to the liver: Topas Therapeutics GmbH and Cour Pharmaceutical Development Co. Inc....
BioCentury | Aug 11, 2016
Product R&D

Selecta spreads tolerance

...cells, the engineered protein antigens will be recognized as self along with the erythrocyte components. Cour Pharmaceutical Development Co. Inc....
...AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Anokion S.A., Ecublens, Switzerland Brigham and Women's Hospital, Boston, Mass. Cour Pharmaceutical Development Co. Inc....
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...discovery or preclinical deals for GI diseases since, including deals in December and January with Cour Pharmaceutical Development Co. Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Cour Pharmaceutical Development Co. Inc....
BioCentury | Feb 4, 2016
Translation in Brief

Peanut butter fingerprints

...multiple allergens. The partners also market the mAb for urticaria. Nadeau is also working with Cour Pharmaceutical Development Co. Inc....
BioCentury | Jan 28, 2016
Translation in Brief

Enterome's Entrée

...the space of a month. Takeda's GI Drug Discovery Unit (DDU) announced a deal with Cour Pharmaceutical Development Co. Inc....
BioCentury | Jan 18, 2016
Company News

Cour Pharmaceutical, Takeda deal

...which Takeda exercises its option. The companies declined to provide further financial terms or details. Cour Pharmaceutical Development Co. Inc....
BioCentury | May 26, 2014
Company News

Cour Pharmaceutical board of directors update

Cour Pharmaceutical Development Co. Inc. , Elmhurst, Ill. Business: Inflammation, Autoimmune, Endocrine/Metabolic Appointed: Catherine Mackey as chairman, formerly SVP of worldwide R&D at Pfizer Inc. WIR Staff autoimmune Inflammation...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Inflammation

...sites of inflammation and disease symptoms compared with neutral nanoparticles or vehicle. Ongoing studies at Cour Pharmaceutical Development Co. Inc....
...doi:10.1038/scibx.2014.148 Published online Feb. 6, 2014 Patented by Getts Consulting and Project Management; licensed to Cour Pharmaceutical...
Items per page:
1 - 10 of 11